- Home
- IMTE vs REVB Comparison
IMTE vs REVB Comparison
Compare IMTE & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTE
- REVB
- Stock Information
- Founded
- IMTE 2008
- REVB 2020
- Country
- IMTE Malaysia
- REVB United States
- Employees
- IMTE N/A
- REVB N/A
- Industry
- IMTE Consumer Electronics/Appliances
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- IMTE Consumer Staples
- REVB Health Care
- Exchange
- IMTE Nasdaq
- REVB Nasdaq
- Market Cap
- IMTE 3.3M
- REVB 3.4M
- IPO Year
- IMTE N/A
- REVB N/A
- Fundamental
- Price
- IMTE $1.11
- REVB $1.48
- Analyst Decision
- IMTE
- REVB
- Analyst Count
- IMTE 0
- REVB 0
- Target Price
- IMTE N/A
- REVB N/A
- AVG Volume (30 Days)
- IMTE 1.2M
- REVB 994.9K
- Earning Date
- IMTE 09-26-2025
- REVB 11-07-2025
- Dividend Yield
- IMTE N/A
- REVB N/A
- EPS Growth
- IMTE N/A
- REVB N/A
- EPS
- IMTE N/A
- REVB N/A
- Revenue
- IMTE $123,337.00
- REVB N/A
- Revenue This Year
- IMTE N/A
- REVB N/A
- Revenue Next Year
- IMTE N/A
- REVB N/A
- P/E Ratio
- IMTE N/A
- REVB N/A
- Revenue Growth
- IMTE 4.75
- REVB N/A
- 52 Week Low
- IMTE $0.51
- REVB $1.35
- 52 Week High
- IMTE $3.17
- REVB $60.48
- Technical
- Relative Strength Index (RSI)
- IMTE 52.47
- REVB 36.21
- Support Level
- IMTE $0.96
- REVB $1.40
- Resistance Level
- IMTE $1.29
- REVB $1.59
- Average True Range (ATR)
- IMTE 0.12
- REVB 0.10
- MACD
- IMTE 0.00
- REVB 0.02
- Stochastic Oscillator
- IMTE 36.52
- REVB 46.43
About IMTE Integrated Media Technology Limited
Integrated Media Technology Ltd is engaged in the development, sale, and distribution of autostereoscopic 3D display, 3D conversion equipment, and software, development, and sale of 3D autostereoscopic technology, and the provision of 3D consultancy services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).